Press Releases

Year

Sep 16, 2019

Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen

Suvodirsen is an investigational stereopure oligonucleotide in development for the treatment of DMD patients amenable to exon 51 skipping Clinical dystrophin data from interim analysis of ongoing OLE study on track for 4Q 2019 DYSTANCE 51 global Phase 2/3 trial is underway CAMBRIDGE, Mass.

Sep 06, 2019

Wave Life Sciences to Host Analyst and Investor Research Day on October 7, 2019

Wave leadership to present updates on multiple preclinical programs and discuss advances in PRISM™ platform CAMBRIDGE, Mass. , Sept. 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for

Sep 05, 2019

Wave Life Sciences Expands Board of Directors with Three New Appointments

New independent directors bring deep expertise in drug development, commercial operations and government affairs CAMBRIDGE, Mass. , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments

Aug 26, 2019

Wave Life Sciences to Present at the Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass. , Aug. 26, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive

Aug 06, 2019

Wave Life Sciences Appoints Mark Baldry as Chief Commercial Officer

Commercial build-out to support anticipated launch of suvodirsen and other future commercialized products CAMBRIDGE, Mass. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for

Jul 29, 2019

Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update

Interim efficacy data from ongoing suvodirsen open-label extension study on track for 4Q 2019 Phase 2/3 DYSTANCE 51 global, placebo-controlled study of suvodirsen initiated First topline data from PRECISION-HD clinical program expected by year-end CAMBRIDGE, Mass.

Jun 27, 2019

Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen

Global study designed to assess the efficacy and safety of suvodirsen in DMD patients amenable to exon 51 skipping Results intended to support regulatory approvals globally CAMBRIDGE, Mass. , June 27, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines

Jun 12, 2019

Wave Life Sciences to Present at Parent Project Muscular Dystrophy 2019 Annual Conference

CAMBRIDGE, Mass. , June 12, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Michael Panzara , MD, MPH, Chief Medical Officer,

May 22, 2019

Wave Life Sciences to Present at the Jefferies 2019 Healthcare Conference

CAMBRIDGE, Mass. , May 22, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive

May 10, 2019

Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update

CAMBRIDGE, Mass. , May 10, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the first quarter ended March 31,